Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab + Glucocorticoids for Acute NMO/NMOSD Relapse
NCT02276963Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ublituximab in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Johns Hopkins University. Primary endpoints: Expanded Disability Status Scale at 90 days and Adverse Events up to 9 months. Started Jan 2016; status: completed.
02
Drugs
ublituximab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT02276963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276963.